George Garibaldi and Paolo Zocchi proposed as new independent, non-executive Board members
Patrick Langlois and Luca Benatti to step down after long-standing service
Full Annual
Ad hoc announcement pursuant to Art. 53 LR
Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of
Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant
Milan, Italy, and Morristown, NJ, USA, January 7, 2026 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development
Ad hoc announcement pursuant to Art. 53 LR
EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044
Evenamide is currently being
Morristown, NJ, USA, and Milan, Italy, December 22, 2025, 07:00 am ET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on
Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 2 is a global, randomized, double-blind, placebo-controlled 12-week Phase III clinical study designed to enroll at least 400
New post-hoc analyses highlighting the clinical benefit of evenamide for patients with treatment-resistant schizophrenia (TRS) or those inadequately responding to their
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 16, 2025, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a
The importance of glutamate release modulation by evenamide used as an add-on therapy for patients with schizophrenia inadequately responding to their second-
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
